Head and neck cancer drug combo safety trial halted early
NCT ID NCT06056310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study aimed to see if adding the drug xevinapant to standard chemoradiotherapy is safe for people with advanced head and neck cancer that cannot be removed by surgery. The study planned to enroll 18 participants but was terminated early. The main focus was on side effects and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105, United States
-
Centre Hospitalier de l'Ardenne - PARENT
Libramont, Belgium
-
China Medical University Hospital
Taichung, Taiwan
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Clinica Universidad de Navarra (MAD) - Oncology Service
Madrid, Spain
-
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
-
Hospital Universitario Fundacion Jimenez Diaz - Oncology
Madrid, Spain
-
Hospital Universitario Virgen del Rocio - Oncology Service
Seville, Spain
-
ICO Girona - Hospital Universitari de Girona Dr Josep Trueta - Servicio de Oncologia Medica
Girona, Spain
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
Karmanos Cancer Institute - PARENT
Detroit, Michigan, 48201, United States
-
Konkuk University Medical Center
Seoul, South Korea
-
Montefiore Medical Center PRIME
The Bronx, New York, 10467, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
National Taiwan University Hospital
Taipei, Taiwan
-
Pusan National University Hospital
Busan, South Korea
-
Pusan National University Yangsan Hospital
Yangsan, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, South Korea
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
Universitair Ziekenhuis Gent - Medical Oncology
Ghent, Belgium
-
Uza - Parent
Edegem, Belgium
-
Vitaz
Sint-Niklaas, Belgium